Comparative Pharmacology
Head-to-head clinical analysis: BENOXINATE HYDROCHLORIDE versus GOPRELTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENOXINATE HYDROCHLORIDE versus GOPRELTO.
BENOXINATE HYDROCHLORIDE vs GOPRELTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium channel blocker; stabilizes neuronal membrane and prevents initiation and transmission of nerve impulses.
Topical analgesic; produces local anesthesia by reversibly blocking sodium channels in nerve cell membranes, inhibiting nerve impulse conduction.
1-2 drops of 0.4% solution in the conjunctival sac up to every 5-10 minutes for surface anesthesia, not exceeding 7 doses per procedure.
100 mcg (0.1 mg) administered as a single intra-articular injection per affected joint. Maximum total dose per treatment session is 4 mL (4 mg).
None Documented
None Documented
2.5-3.5 minutes in plasma; extremely short half-life due to rapid hydrolysis by plasma esterases, limiting systemic exposure after ocular administration
Terminal elimination half-life is 2.5 hours in patients with normal renal function. Clinical context: In moderate renal impairment (CrCl 30-40 mL/min), half-life is prolonged to 3.2 hours; in severe impairment, up to 6 hours.
Primarily renal; approximately 70-80% excreted unchanged in urine; minor biliary/fecal elimination (<10%)
Primarily renal elimination: 70% as unchanged drug, 15% as metabolites. Biliary/fecal excretion accounts for approximately 10%.
Category C
Category C
Topical Anesthetic
Topical Anesthetic